Medmix AG's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 41.23.
Medmix AG's Days Inventory for the
six
months ended in Dec. 2025 was 96.74.
Medmix AG's Days Payable for the
six
months ended in Dec. 2025 was 57.5.
Therefore, Medmix AG's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 80.47.
Medmix AG (OTCPK:MDMXF) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Medmix AG Cash Conversion Cycle Related Terms
Medmix AG Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Medmix AG's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDMXF vs GEV, ETN, PH: Cash Conversion Cycle Comparison
For the Specialty Industrial Machinery subindustry, Medmix AG's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medmix AG Cash Conversion Cycle vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Medmix AG's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Medmix AG's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Medmix AG's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medmix AG (MDMXF) has a Cash Conversion Cycle of 80.47 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medmix AG and its competitors.
Is Medmix AG's Cash Conversion Cycle too high?
Medmix AG's current Cash Conversion Cycle is 80.47. The Industrial Products industry median Cash Conversion Cycle is 122.24. Medmix AG's value of 80.47 is 34.2% below this industry median. Overall, Medmix AG has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's Cash Conversion Cycle compare to GEV and ETN?
Medmix AG's Cash Conversion Cycle of 80.47 can be compared against companies in the Industrial Products industry. The industry median Cash Conversion Cycle is 122.24. Medmix AG's value of 80.47 is 34.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for an Industrial Products company?
The median Cash Conversion Cycle among Industrial Products companies is 122.24, based on 3,035 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medmix AG's current Cash Conversion Cycle of 80.47 is 34.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medmix AG and its competitors. For the Industrial Products industry, the median Cash Conversion Cycle is 122.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current Cash Conversion Cycle is 80.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current Cash Conversion Cycle of 80.47. The stock's GF Value™ is $26.13, compared to a current price of $17.40 — trading 33.4% below its estimated fair value. The current Cash Conversion Cycle is 80.47 and 34.2% below the Industrial Products industry median of 122.24. Medmix AG's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Medmix AG (MDMXF), the current Cash Conversion Cycle is 80.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medmix AG (MDMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued.
The current stock price of $17.40 is trading 33.4% below its estimated GF Value™ of $26.13.
Key valuation signals for MDMXF:
Cash Conversion Cycle: 80.47
GF Value™: $26.13 vs. price of $17.40 (33.4% below fair value)
Industry Position: 34.2% below the Industrial Products median
No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
61GF Score
Get the complete analysis for MDMXF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDMXF has been successfully added to your 
